Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 12/20 | 0.56 |
| ▸ | ESR1 | P03372 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 4/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382898 | 1.00 | ESR2 (0.56) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL17327330 | 1.00 | ESR2 (0.56) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL10197496 | 0.88 | DGAT1 (0.47) | ESR2ESR1CYP3A4CYP2C9DGAT1 | |
| SCHEMBL16969312 | 0.87 | ESR2 (0.51) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL4673308 | 0.86 | DGAT1 (0.46) | ESR2ESR1CYP3A4CYP2C9DGAT1 | |
| SCHEMBL18763690 | 0.86 | DGAT1 (0.51) | DGAT1MIFALDH1A1LMNAMAPT | |
| SCHEMBL28817040 | 0.86 | IDO1 (0.56) | DGAT1MAPT | |
| SCHEMBL17327303 | 0.86 | DGAT1 (0.51) | DGAT1MIFALDH1A1LMNAMAPT | |
| SCHEMBL1399745 | 0.86 | DGAT1 (0.51) | ESR2ESR1CYP3A4CYP2C9DGAT1 | |
| SCHEMBL28102452 | 0.86 | DGAT1 (0.46) | ESR2ESR1CYP3A4CYP2C9DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234978-B1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013068439-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5, 4 -F] [1, 4] OXAZEPINE COMPOUNDS AS DGAT1 INHIBITORS | INTERVET INTERNATIONAL B.V. (NL) | 2013-05-16 | — | — | WO | disclosed |
| WO-2012138648-A1 | COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS | IRM LLC (BM) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012122075-A1 | LACTAM DERIVATIVES AS DGAT-1 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012112364-A1 | LACTAM DERIVATIVES AS DGAT-1 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| EP-2408744-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2393811-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | Pfizer Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| EP-2035417-B1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| WO-2010089686-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | disclosed |
| US-20100160397-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| EP-2035417-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2032546-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Astra Zeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008129319-A1 | SALTS OF OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007141517-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141538-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | ESR2 3064/4885ESR1 4104/4885CYP3A4 1304/4885 |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | CDK7, DPYD, DHFR | ESR2 1708/4885ESR1 1422/4885CYP3A4 43/4885 |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | DGAT1, ACAT1, DGAT2 | ESR2 3249/4885ESR1 3803/4885CYP3A4 512/4885 |
| US-20100160397-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | DGAT1, ACAT1, DGAT2 | ESR2 1636/4885ESR1 2281/4885CYP3A4 932/4885 |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | ESR2 3055/4885ESR1 4117/4885CYP3A4 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.